FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2254824090> ?p ?o ?g. }

• W2254824090 endingPage "1584" @default.
• W2254824090 startingPage "1575" @default.
• W2254824090 abstract "Six hundred fourteen previously untreated patients with multiple myeloma were evaluated on this phase III Southwest Oncology Group (SWOG) trial. For remission induction, two noncross-resistant drug combinations (vincristine, melphalan, cyclophosphamide, and prednisone [VMCP] and vincristine, carmustine [BCNU], Adriamycin [doxorubicin; Adria Laboratories, Columbus, OH], and prednisone [VBAP]) were administered with either a direct alternating or a syncopated schedule. Pretreatment serum beta-2 microglobulin (beta 2M) was the single most important prognostic factor for survival (P less than .0001). There was no difference in toxicity, response, or survival by induction chemotherapy schedule (P greater than .7). For consolidation, 180 eligible and responsive patients were randomized to receive either an additional year of VMCP or sequential hemibody radiation (HBI) with vincristine and prednisone (VP) administered between the two HBI courses. Relapse-free survival (26 months) and overall survival (median, 36 months) were better with VMCP than with HBI (median, 20 months and 28 months; P = .04 and .018, respectively). HBI was also evaluated on a nonrandomized basis in 66 patients who achieved either a partial response (PR) or who were nonresponders to induction therapy. While HBI converted 24% of the PR patients to remission status, this effect was only seen in 5% of nonresponding patients. The survival of responsive and nonresponding patients receiving HBI was similar. All HBI groups had an inferior outcome to those receiving VMCP consolidation. Myelosuppression was also significantly worse after HBI. Survival from the time of relapse did not differ between patients randomized to receive VMCP or HBI. Thus HBI induced less durable remissions, but did not render patients less amenable to postrelapse chemotherapy. Our findings do not support the use of HBI in either chemotherapy responsive or nonresponding patients with multiple myeloma." @default.
• W2254824090 created "2016-06-24" @default.
• W2254824090 creator A5009044758 @default.
• W2254824090 creator A5024155531 @default.
• W2254824090 creator A5026709893 @default.
• W2254824090 creator A5029123414 @default.
• W2254824090 creator A5036980145 @default.
• W2254824090 creator A5050240461 @default.
• W2254824090 creator A5064610672 @default.
• W2254824090 creator A5072883151 @default.
• W2254824090 creator A5080175936 @default.
• W2254824090 creator A5090720942 @default.
• W2254824090 date "1990-09-01" @default.
• W2254824090 modified "2023-09-26" @default.
• W2254824090 title "Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study." @default.
• W2254824090 cites W1580788756 @default.
• W2254824090 cites W1972264308 @default.
• W2254824090 cites W1979300931 @default.
• W2254824090 cites W1991147714 @default.
• W2254824090 cites W2003236449 @default.
• W2254824090 cites W2006382315 @default.
• W2254824090 cites W2030750674 @default.
• W2254824090 cites W2033293830 @default.
• W2254824090 cites W2053805295 @default.
• W2254824090 cites W2094509288 @default.
• W2254824090 cites W2099704297 @default.
• W2254824090 cites W2174802444 @default.
• W2254824090 cites W2413853954 @default.
• W2254824090 cites W2440945044 @default.
• W2254824090 doi "https://doi.org/10.1200/jco.1990.8.9.1575" @default.
• W2254824090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2131793" @default.
• W2254824090 hasPublicationYear "1990" @default.
• W2254824090 type Work @default.
• W2254824090 sameAs 2254824090 @default.
• W2254824090 citedByCount "54" @default.
• W2254824090 countsByYear W22548240902012 @default.
• W2254824090 countsByYear W22548240902013 @default.
• W2254824090 countsByYear W22548240902014 @default.
• W2254824090 countsByYear W22548240902017 @default.
• W2254824090 countsByYear W22548240902020 @default.
• W2254824090 crossrefType "journal-article" @default.
• W2254824090 hasAuthorship W2254824090A5009044758 @default.
• W2254824090 hasAuthorship W2254824090A5024155531 @default.
• W2254824090 hasAuthorship W2254824090A5026709893 @default.
• W2254824090 hasAuthorship W2254824090A5029123414 @default.
• W2254824090 hasAuthorship W2254824090A5036980145 @default.
• W2254824090 hasAuthorship W2254824090A5050240461 @default.
• W2254824090 hasAuthorship W2254824090A5064610672 @default.
• W2254824090 hasAuthorship W2254824090A5072883151 @default.
• W2254824090 hasAuthorship W2254824090A5080175936 @default.
• W2254824090 hasAuthorship W2254824090A5090720942 @default.
• W2254824090 hasConcept C126322002 @default.
• W2254824090 hasConcept C141071460 @default.
• W2254824090 hasConcept C143998085 @default.
• W2254824090 hasConcept C168563851 @default.
• W2254824090 hasConcept C2776364478 @default.
• W2254824090 hasConcept C2776611710 @default.
• W2254824090 hasConcept C2776694085 @default.
• W2254824090 hasConcept C2776755627 @default.
• W2254824090 hasConcept C2778684742 @default.
• W2254824090 hasConcept C2778720950 @default.
• W2254824090 hasConcept C2779429289 @default.
• W2254824090 hasConcept C2779434656 @default.
• W2254824090 hasConcept C2780147359 @default.
• W2254824090 hasConcept C2781303535 @default.
• W2254824090 hasConcept C71924100 @default.
• W2254824090 hasConceptScore W2254824090C126322002 @default.
• W2254824090 hasConceptScore W2254824090C141071460 @default.
• W2254824090 hasConceptScore W2254824090C143998085 @default.
• W2254824090 hasConceptScore W2254824090C168563851 @default.
• W2254824090 hasConceptScore W2254824090C2776364478 @default.
• W2254824090 hasConceptScore W2254824090C2776611710 @default.
• W2254824090 hasConceptScore W2254824090C2776694085 @default.
• W2254824090 hasConceptScore W2254824090C2776755627 @default.
• W2254824090 hasConceptScore W2254824090C2778684742 @default.
• W2254824090 hasConceptScore W2254824090C2778720950 @default.
• W2254824090 hasConceptScore W2254824090C2779429289 @default.
• W2254824090 hasConceptScore W2254824090C2779434656 @default.
• W2254824090 hasConceptScore W2254824090C2780147359 @default.
• W2254824090 hasConceptScore W2254824090C2781303535 @default.
• W2254824090 hasConceptScore W2254824090C71924100 @default.
• W2254824090 hasIssue "9" @default.
• W2254824090 hasLocation W22548240901 @default.
• W2254824090 hasLocation W22548240902 @default.
• W2254824090 hasOpenAccess W2254824090 @default.
• W2254824090 hasPrimaryLocation W22548240901 @default.
• W2254824090 hasRelatedWork W1923009304 @default.
• W2254824090 hasRelatedWork W1996057688 @default.
• W2254824090 hasRelatedWork W2008183271 @default.
• W2254824090 hasRelatedWork W2042840632 @default.
• W2254824090 hasRelatedWork W2051791220 @default.
• W2254824090 hasRelatedWork W2254824090 @default.
• W2254824090 hasRelatedWork W2398340504 @default.
• W2254824090 hasRelatedWork W2400982915 @default.
• W2254824090 hasRelatedWork W2413876151 @default.
• W2254824090 hasRelatedWork W2181721065 @default.
• W2254824090 hasVolume "8" @default.
• W2254824090 isParatext "false" @default.

• next